Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions

Open access
Curran, Kevin J., Pegram, Hollie J., Brentjens, Renier J.·2012·The Journal of Gene Medicine

Abstract

Background: The genetic engineering of T cells through the introduction of a chimeric antigen receptor (CAR) allows for generation of tumor‐targeted T cells. Once expressed by T cells, CARs combine antigen‐specificity with T cell activation in a single fusion molecule. Most CARs are comprised of an antigen‐binding domain, an extracellular spacer/hinge region, a trans‐membrane domain and an intracellular signaling domain resulting in T cell activation after antigen binding. Methods: We performed a search of the literature regarding tumor immunotherapy using CAR‐modified T cells to provide a concise review of this topic. Results: This review aims to focus on the elements of CAR design required for successful application of this technology in cancer immunotherapy. Most notably, proper target antigen selection, co‐stimulatory signaling, and the ability of CAR‐modified T cells to traffic, persist and retain function after adoptive transfer are required for optimal tumor eradication. Furthermore, recent clinical trials have demonstrated tumor burden and chemotherapy conditioning before adoptive transfer as being critically important for this therapy. Future research into counteracting the suppressive tumor microenvironment and the ability to activate an endogenous anti‐tumor response by CAR‐modified T cells may enhance the therapeutic potential of this treatment. Conclusions: In conclusion, CAR‐modified T cell therapy is a highly promising treatment for cancer, having already demonstrated both promising preclinical and clinical results. However, further modification and additional clinical trials will need to be conducted to ultimately optimize the anti‐tumor efficacy of this approach. Copyright © 2012 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jgm.2604

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 251

Metadata

Authors
Curran, K. J., Pegram, H. J., & Brentjens, R. J.
Venue
The Journal of Gene Medicine
Publisher
Wiley
Published
2012-06
Volume
14
Issue
6
Pages
405-415
ISSN
  • 1099-498X (ISSN-L)
  • 1521-2254
OpenAlex
W1607012924
Cited by
251
References
8
FWCI
10.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. https://app.cochat.ai/papers/10.1002/jgm.2604
The paper
Curran, K. J., Pegram, H. J., & Brentjens, R. J. (2012). Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.2604

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.